Breakthru Medicine
PrivateLast Round
Series A
Jan 29, 2026
Total Funding Raised
$60M
Company Overview
Breakthru Medicine is an oncology company developing therapies for solid cancers using novel antibody-drug conjugates (ADCs), small molecules, and molecular glues.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Precision Medicine, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Breakthru Medicine Comps
Public and private peers based on sector, stage, and business model.
Breakthru Medicine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 29, 2026 |
Breakthru Medicine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Eshelman Ventures | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 29, 2026
Company emerges from stealth with Series A financing.
Breakthru Medicine Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Breakthru Medicine's valuation, stock price, and market status.
